SG11201811223YA - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- SG11201811223YA SG11201811223YA SG11201811223YA SG11201811223YA SG11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- yield
- publication
- date
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011110111111111 111MEMME 11101111 (10) International Publication Number WO 2018/015175 A9 W O 20 18/0 15 175 A9 25 January 2018 (25.01.2018) W 1 PO I PCT (51) International Patent Classification: A61K 9/16 (2006.01) A61K 36/48 (2006.01) A61K 31/201 (2006.01) A61K 9/20 (2006.01) A61K 31/202 (2006.01) (21) International Application Number: PCT/EP2017/066983 (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1611920.8 08 July 2016 (08.07.2016) GB (71) Applicant: ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE). (72) Inventors: VON CORSWANT, Christian; AstraZeneca AB, SE-431 83 Molndal (SE). BORDES, Romain; Chalmers tekniskahogskola AB Kemivagen 4, 412 96 Gote- borg (SE). HJELM JONASSON, Simon, Peter, Michael; Chalmers tekniska hogskola AB Kemivagen 4, 412 96 Gote- borg (SE). (74) Agent: TTOFI, Evangelia; Medlmmune Limited Milstein Building, Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: PHARMACEUTICAL COMPOSITIONS 90 80 70 60 .13 50 40 30 20 10 0 O Cyclone Yield • Collemor Yield 4-1-S 4-1-0 4-0.5 S 4 0.5 0 2 1 S 2-1-2 0.5-S 2-0.5-0 Emulsion Composition Figure 1. Yield for the spray - drying process of eight batches with varying compositions. (57) : The present application relates to solid pharmaceutical compositions and solid dosage forms containing them which comprise oils as their active pharmaceutical ingredient. Methods of preparing the compositions and their uses are described. [Continued on next page] WO 2018/015175 A9 IMEDIM011111 11111111EIDIO0 IIM11111111111111111111110111111111111 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) (48) Date of publication of this corrected version: 29 March 2018 (29.03.2018) (15) Information about Correction: see Notice of 29 March 2018 (29.03.2018)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1611920.8A GB201611920D0 (en) | 2016-07-08 | 2016-07-08 | Pharmaceutical compositions |
PCT/EP2017/066983 WO2018015175A1 (en) | 2016-07-08 | 2017-07-06 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811223YA true SG11201811223YA (en) | 2019-01-30 |
Family
ID=56890842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811223YA SG11201811223YA (en) | 2016-07-08 | 2017-07-06 | Pharmaceutical compositions |
Country Status (20)
Country | Link |
---|---|
US (1) | US20200254046A1 (en) |
EP (1) | EP3481377A1 (en) |
JP (1) | JP2019520393A (en) |
KR (1) | KR20190026816A (en) |
CN (1) | CN109414409A (en) |
AU (1) | AU2017298873B2 (en) |
BR (1) | BR112019000240A2 (en) |
CA (1) | CA3029331A1 (en) |
CL (1) | CL2019000042A1 (en) |
CO (1) | CO2019000083A2 (en) |
CR (1) | CR20190007A (en) |
DO (1) | DOP2019000002A (en) |
EA (1) | EA201990162A1 (en) |
GB (1) | GB201611920D0 (en) |
IL (1) | IL263999A (en) |
MX (1) | MX2019000255A (en) |
PE (1) | PE20190321A1 (en) |
PH (1) | PH12019500024A1 (en) |
SG (1) | SG11201811223YA (en) |
WO (1) | WO2018015175A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071461A1 (en) * | 2020-10-02 | 2022-04-07 | 住友精化株式会社 | Viscous composition |
WO2022071463A1 (en) * | 2020-10-02 | 2022-04-07 | 住友精化株式会社 | Viscous composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE382597T1 (en) * | 2002-06-17 | 2008-01-15 | Resolvyx Pharmaceuticals | ANALOGUE OF OMEGA-3 PUFAS DERIVED LIPID MEDIATORS AND METHODS OF APPLICATION |
WO2008145183A1 (en) * | 2007-05-30 | 2008-12-04 | Nestec S.A. | Oil-in-water emulsion and its use for the delayed release of active elements |
GB2465988A (en) * | 2008-12-03 | 2010-06-09 | Omegatri As | Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate |
JP6176894B2 (en) * | 2009-03-09 | 2017-08-09 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | Composition comprising fatty acid oil mixture and surfactant, and method and use thereof |
CN102512664B (en) * | 2010-12-31 | 2015-04-01 | 舒泰神(北京)生物制药股份有限公司 | Nerve growth factor composition |
EP3348262A1 (en) | 2012-01-06 | 2018-07-18 | Omthera Pharmaceuticals Inc. | Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
-
2016
- 2016-07-08 GB GBGB1611920.8A patent/GB201611920D0/en not_active Ceased
-
2017
- 2017-07-06 AU AU2017298873A patent/AU2017298873B2/en not_active Ceased
- 2017-07-06 EP EP17737254.7A patent/EP3481377A1/en not_active Withdrawn
- 2017-07-06 KR KR1020197003215A patent/KR20190026816A/en not_active Application Discontinuation
- 2017-07-06 CN CN201780041970.8A patent/CN109414409A/en active Pending
- 2017-07-06 WO PCT/EP2017/066983 patent/WO2018015175A1/en unknown
- 2017-07-06 SG SG11201811223YA patent/SG11201811223YA/en unknown
- 2017-07-06 BR BR112019000240-5A patent/BR112019000240A2/en not_active Application Discontinuation
- 2017-07-06 US US16/316,228 patent/US20200254046A1/en not_active Abandoned
- 2017-07-06 CA CA3029331A patent/CA3029331A1/en not_active Abandoned
- 2017-07-06 MX MX2019000255A patent/MX2019000255A/en unknown
- 2017-07-06 CR CR20190007A patent/CR20190007A/en unknown
- 2017-07-06 PE PE2018003289A patent/PE20190321A1/en unknown
- 2017-07-06 JP JP2019500328A patent/JP2019520393A/en not_active Withdrawn
- 2017-07-06 EA EA201990162A patent/EA201990162A1/en unknown
-
2018
- 2018-12-27 IL IL263999A patent/IL263999A/en unknown
-
2019
- 2019-01-03 PH PH12019500024A patent/PH12019500024A1/en unknown
- 2019-01-03 DO DO2019000002A patent/DOP2019000002A/en unknown
- 2019-01-07 CL CL2019000042A patent/CL2019000042A1/en unknown
- 2019-01-08 CO CONC2019/0000083A patent/CO2019000083A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB201611920D0 (en) | 2016-08-24 |
PH12019500024A1 (en) | 2019-11-04 |
WO2018015175A9 (en) | 2018-03-29 |
KR20190026816A (en) | 2019-03-13 |
US20200254046A1 (en) | 2020-08-13 |
CO2019000083A2 (en) | 2019-01-18 |
JP2019520393A (en) | 2019-07-18 |
CR20190007A (en) | 2019-03-05 |
AU2017298873B2 (en) | 2020-04-30 |
AU2017298873A1 (en) | 2019-02-14 |
PE20190321A1 (en) | 2019-03-04 |
CA3029331A1 (en) | 2018-01-25 |
IL263999A (en) | 2019-01-31 |
EP3481377A1 (en) | 2019-05-15 |
BR112019000240A2 (en) | 2019-04-16 |
CN109414409A (en) | 2019-03-01 |
CL2019000042A1 (en) | 2019-04-12 |
EA201990162A1 (en) | 2019-06-28 |
DOP2019000002A (en) | 2019-03-31 |
MX2019000255A (en) | 2019-05-27 |
WO2018015175A1 (en) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201804587QA (en) | Isoindole compounds | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |